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ABSTRACT
Background: Many people with seizure disorder experience reproductive endocrine dysfunction
(RED). The extent to which RED is due to intrinsic aspects of seizure disorder, and/or therapies
used to manage epilepsy, is not well understood. Many anti-epileptic drugs (AEDs), such as
phenytoin or valproate, can have effects that alter endocrine status. Phenytoin is a cytochrome
p450 enzyme-inducing drug. Valproate is a cytochrome p450 enzyme-reducing AED. Objective:
To evaluate the effects and mechanism of some AEDs on RED in a rodent model. Hypothesis: If
AEDs produce RED in part by altering the activities of cytochrome p450 enzymes, then AEDs
that disrupt estrous cyclicity and/or sexual behavior will alter levels of steroids, that are products
of p450 enzymes, in brain areas mediating such responses.
Methods: Phenytoin (50 mg/kg, IP), valproate (165 mg/kg, IP), or placebo (40% propylene
glycol and 10% ethanol in distilled water, IP) was administered to gonadally-intact, female
Long-Evans rats, twice daily for four weeks. Estrous cyclicity was monitored daily. After 4
weeks, when rats were in proestrous, they were tested for sexual receptivity. Immediately after
completion of sex testing, brain and trunk blood were collected for later radioimmunoassay.
Ovaries and uterus were collected and weighed as a measure of trophic effects. Results:
Phenytoin and valproate disrupted the estrous cycle and increased aggressive behavior of rats.
The levels of 5-pregnan-3-ol-20-one (3,5-THP) in the hippocampus and hypothalamus of
phenytoin-treated rats were significantly lower than in controls. Levels of progesterone (P 4) in
plasma were lower among rats administered valproate compared to the controls. Conclusion:
AEDs, such as phenytoin and valproate, disrupted estrous cylicity and sexual behavior of female
rats, and reduced levels of hypothalamic, hippocampal, and circulating progestogens, which are
products of p450 enzymes.
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INTRODUCTION
Epilepsy is a serious neurological disorder affecting over 3 million Americans and over
50 million people worldwide (McHugh and Delanty, 2008). Those who suffer from epilepsy
outnumber those suffering from multiple sclerosis, cerebral palsy, muscular dystrophy and
Parkinson's disease combined (Meachem, 2009). Furthermore, approximately 200,000 new cases
of epilepsy are diagnosed each year, 70% of which appear to be asymptomatic. Epilepsy affects
every age group, from infants to the elderly, and can develop at any stage in life. However, in
most cases it begins in childhood, at the onset of puberty. On average, a person with epilepsy
faces a mortality rate that is 2-3 times greater than that of an unaffected person; (Nouri, 2006).
The risk of sudden death among epileptics is 24 times greater than that of the general population
(Meachem, 2009). In summary, epilepsy is a pressing problem worldwide.
Epilepsy is associated with Reproductive Endocrine Dysfunction, or RED, in both men
and women. Women with epilepsy face a host of challenges, including disruption in reproductive
health. Compared to the general population, women with epilepsy have substantially higher
chances of developing syndromes associated with infertility, such as polycystic ovary syndrome,
hypothalamic amenorrhea, or functional hyperprolactinemia (Bauer and Cooper-Mahkorn,
2008). In a large clinical center 50% of women with epilepsy were found to have menstrual
abnormalities, 20% amenorrheic and 30% anovulatory (Engel et al, 2007). Epidemiological
studies have shown that 10%-25% of women with epilepsy suffer from Polycystic Ovary
Syndrome (PCOS) compared with 4-6% of women in the general population (Bauer et al, 2002).
A study conducted in the Greater London area showed that women with epilepsy had a
significantly reduced birth rate in comparison with women of the general population (Wallace et
al, 1998). In addition, studies on sexual function in women with epilepsy reported variable
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frequencies of sexual dysfunction: 14% in Egypt, 29% in Scandinavia, 36-50% in the United
States (Morrell, 1998). This demonstrates that RED is a common problem among women with
epilepsy.
It is well established that steroid hormones have great influence on reproductive
endocrine function. The central nervous system (CNS) acts both as a target and source of sex
steroids and of their metabolites. Neuroactive steroids are steroid hormones that produce
functional effects through actions in the CNS. They mediate many diverse neuroendocrine
functions (Baulieu, 1997). Among those functions are the release of GnRH, LH, and FSH which
are important in ovulation and regulation of the duration of menstrual cycles. Neuroactive
steroids also influence female sexual behavior (Frye et al, 2006). An important steroid hormone
which influences female sexual behavior is Progesterone (P4), which like all other steroid
hormones, is derived from cholesterol. Cholesterol must first be converted to pregenolone, which
when catalyzed by cytochrome P450 forms progesterone. P4 is the precursor of the mineral
corticoid aldosterone which is then reduced to form the many important byproducts such as
testosterone, estradiol, and the metabolite of P4, 5 alpha-pregnane-3,20-dione (5-DHP), which is
further broken down into 5-pregnan-3-ol-20-one (3,5-THP) (Frye and Paris, 2008). To
gain insights into the nature of the effects of steroid hormones on reproductive endocrine
function and sexual behavior, a rat model is used in this study.
In rodent models, sexual activity is dependent on a modulator of lordosis (the
stereotypical posture that female rodents exhibit in response to male-typical stimuli), and the
control of behavioral processes such as aggression and anxiety (Frye and Rhodes, 2008). 3,5THP, a metabolite of P4, has been shown to mediate such behaviors. Rats have elevated 3,5THP in behavioral estrus, a period during which they are most receptive to mating and
demonstrate more exploration, anti-anxiety, and pro-social behaviors than rats in diestrous, a
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period in which they are least receptive to mating (Frye, Paris, and Rhodes 2008). Elevated
3,5-THP levels, independent of P4, also increase hopping and darting behavior (proceptivity)
that female rats make toward male rats to achieve sexual contacts. Overall, the metabolism and
presence of 3,5-THP is a critical factor in the success of modulating rodent mating.
3,5-THP has multiple targets in the brain to modulate its effects on sexual behavior. In
the ventral tegmental area (VTA) of the midbrain, 3,5-THP works to control the
consummatory aspects of sexual behavior; this includes stimulating and controlling lordosis.
Decreased 3,5-THP concentrations in the midbrain region significantly decrease lordosis
responses (Frye et al., 2008). The 3,5-THP concentrations at GABAergic substrates in the
hippocampus and hypothalamus work to mediate motivational and anxiety aspects of sexual
behavior. When there are increased levels of 3,5-THP in the hippocampus, female rats
demonstrate less species-typical anxiety-like behavior and conspecific-avoidance, spending more
time in affiliation with their mates (Frye and Rhodes, 2008). Thus, the role of 3,5-THP in the
different parts of the rodent’s brain dramatically affect mating behavior.
Anti epileptic drugs (AEDs) have the potential to affect brain function and, more
specifically, the production and metabolism of steroid hormones, like 3,5-THP, which affect
sexual behavior. Studies done on women taking AEDs show that the occurrence of RED is
significantly higher in those that take cytochrome p450 enzyme-inducing AEDs, such as
phenytoin, than those that do not (Sheth and Montouris, 2008). AEDs which induce cytochrome
p450 increase the metabolism of gonadal and adrenal steroid hormones which induce the
synthesis of sex hormone-binding globulin. As the potential for protein binding ability increases,
the biologically active fraction of hormone levels in circulation decreases. This reduction in sex
steroid hormones is commonly associated with sexual dysfunction (Morrell, 2005). Prior studies
have demonstrated that serum concentrations of estrogens and androgens are indeed reduced in
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women with epilepsy receiving enzyme inducing AEDs (Morrell, 2005). This, in turn, is
associated with reproductive endocrine dysfunction such as polycystic ovaries and
hypogonadotropic hypogonadism (Macphee et. al., 1998; Stoffel-Wagner et. al., 1998). Similar
to cytochrome p450 enzyme inducing AEDs, cytochrome p450 enzyme-reducing AEDs, such as
valproate, have marked effects on steroid hormone levels. Enzyme reducing AEDs are
progesterone antagonists and they dramatically increase the presence of circulating androgens
(Isojarivi et. al., 2004). This consequently disrupts the ratio of androgens to estradiol, causing
reproductive problems such as polycystic ovaries (Morrell, 2003). The critical ratio of
androgens to estradiol is in other words the ratio between female and male sex steroid hormones.
The most common type of RED experienced with valproate users is anovulatory cycles (Morrell,
2004). Overall, the AEDs, phenytoin and valproate, which have been shown to alter steroid
hormone levels in the brain, valproate reducing the amount of estradiol and progesterone in
circulation and phenytoin reducing the metabolically active levels of steroid hormones, can cause
many undesirable and serious side effects.
Studies such as this one are critical in understanding and evaluating the effects and
mechanism of some AEDs on RED. It is difficult, however, to determine whether RED is a
direct result of epilepsy or the AED treatment used to combat the disorder. The rat model is
helpful in isolating the effects of the AEDs on steroid hormone functions as rats are epilepsy
free. Subjecting human beings to similar epilepsy experimentation presents ethical dilemmas as
it is simply not feasible to withhold treatment from a control group due to the devastating
consequences of epileptic seizures which may include brain damage or death. The data suggests
phenytoin, a cytochrome p450 enzyme inducing drug, and valproate, a cytochrome p450 enzyme
reducing drug, could have marked effects on steroid hormone levels. To determine if this is the
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case, we correlated steroid levels in the brain areas controlling estrous cyclicity and sexual
behavior in rats treated with AEDs that potentially produce RED in humans.
MATERIALS & METHODS
These methods were pre-approved by the Institutional Animal Care and Use Committee
at The University at Albany-SUNY.
Subjects
Female, intact rats (N=38) were approximately 50 days old and were acquired from our
breeding colony at The University at Albany-SUNY. Rats were housed in polycarbonate cages (34 rats per cage), in a temperature- (21 ± 1 C) and humidity- (50 ± 5 %) controlled room in our
Laboratory Animal Care Facility. Rats were maintained on a reversed 12 hr light-dark cycle (lights
off at 0800 h) and had ad libitum access to food and water throughout the study.
Determination of Estrous Cycle Phase
Vaginal epithelium was obtained between 0800-0900 h via lavage and examined
microscopically daily to determine the day of the estrous cycle. Cycle phase was determined per
previous methods (Frye, 2001; Marcondes et al., 2002). Briefly, the proestrous phase, the time
when endogenous estrogens and progestogens peak, was characterized by the presence of many
nucleated epithelial cells. The estrous phase, when estrogens are low and progestogens are
declining was distinguished by cornification of the vaginal epithelium. Cornification is the
stratification of epidermal tissues and the process of forming an epidermal barrier on the cells
coupled with the production of keratin (Lippens, 2005). It is characterized by cells with very
rugged edges and the loss of nuclei and organelles. The diestrous phase, when estrogens and
progestogens are at nadir, was characterized by the lack of epithelial cells and the presence of
leukocytic cells. Rats were cycled through two estrous cycles (demonstrating proestrous once
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every 4-5 days) prior to manipulation in order to verify typical estrous cyclicity. Only rats that
demonstrated 4-5 day cycles before manipulation were utilized in the study.

Preparation of AED Regimen
AEDs were purchased from Sigma-Aldrich (St. Louis, MO). Phenytoin was dissolved
in a propylene glycol vehicle (40% propylene glycol and 10% ethanol in distilled water) and
valproate was dissolved in 0.9% sodium chloride.
Procedure
Rats were randomly assigned to receive twice daily, intraperitoneal (IP) injections of
phenytoin (50 mg/kg, IP), valproate (165 mg/kg, IP), or a commensurate volume of vehicle (40%
propylene glycol and 10% ethanol in distilled water, IP) at 11:00 h and 15:00 h for at least 28
days. During this time, vaginal cytology was recorded daily. After 28 days of treatment, rats
were tested in the mating paradigm described below at their next sexually-receptive (proestrous)
phase of their estrous cycle. The rats continued to receive AED treatment until sex-testing.
Because of the need to test rats when sexually-receptive, there were differences in the length of
treatment among some rats (the treatment range was 28-33 days) but these differences did not
account for a significant amount of variance on any measure of parameter. Immediately
following completion of sex-testing; brain, ovaries, uterus, and serum were collected and wet
weights were documented. All tissues were stored at -80 ºC until the radioimmunoassay was
performed.
Sex Testing
Sex testing was conducted in a chamber 37.5 x 75 x 30 cm as previously reported (Hardy
& DeBold, 1972; Frye et al. 2000). Sexually-vigorous male studs were briefly paired with
sexually-receptive stimulus females in order to ensure immediate mounting. Each experimental

Antiepileptic drugs and reproductive function 8
female rat was placed in the chamber with a stimulated male and observed until either ten mounts
were achieved, until male ejaculation, or for ten minutes if neither ten mounts nor ejaculation were
achieved. Behavior was observed by two investigators, and mean scores were utilized in all
behavioral analyses. The frequency and intensity of lordosis (quantified by rating of dorsiflexion
on a scale of 0–3) in response to male mounting was recorded (Hardy & DeBold, 1972). In
addition, the frequency of proceptive (hopping, darting, ear-wiggling) and aggressive
(vocalizations, defensive posture) behaviors were recorded as described (Frye et al 2001).
Tissue Preparation
Brains were kept on ice and the midbrain, hippocampus, hypothalamus, and cortex
were removed, and the remaining tissue without the cerebellum was used as a control (“interbrain”) (Frye and Rhodes, 2006ab). Following the extractions of the separate brain regions,
steroids were extracted from brain tissue as described below.
Radioimmunoassay for Steroid Hormones
P4, 5 alpha-pregnane-3,20-dione (5-DHP), 3,5-THP, and Androstane-3a-Diol-G (3-diol)
concentrations were measured using the previously reported methods described below (Choi and
Dallman, 1999; Frye and Bayon, 1999; Frye et al., 1996). Following tissue collection, some
brains were frozen on dry ice, blood was centrifuged, the serum saved, and tissues were stored at
-80 oC for later analysis.
Radioactive Probes
The radioactive probes used for the assays were as follows: [3H] P4 (catalog number
NET-208) with a specific activity of 47.5 Ci/mmol; [3H]3,5-THP (catalog number NET-1047)
with a specific activity of 65.0 Ci/mmol; 5-DHP catalog number (NET-1047) with a specific
activity of 65.0 Ci/mmol, 3-diol (catalog number NET-806) with a specific activity of 41.00
Ci/mmol were purchased from Perkin Elmer (Boston, MA).
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Extraction of Steroids from Serum
P4, 5-DHP, 3,5-THP, and 3-diol were extracted from serum with ether following
incubation with water and 800 cpm of 3H steroid (Frye and Bayon, 1999). Test tubes containing
steroid and ether were evaporated to dryness in a speed vacuum. Dried down samples were
reconstituted with pH 7.2 phosphate assay buffer to the original serum volume.
Extraction of Steroids from Brain Tissues
P4, 5-DHP, 3,5-THP, and 3-diol were extracted from brain tissues following
homogenization with a glass/glass homogenizer in 50% methanol, 1% acetic acid. Tissues were
centrifuged at 3,000 x g and the supernatant was chromatographed on Sepak-cartridges. Steroids
were washed with 50 % methanol then eluted with 100% methanol. Solvents were removed
using a speed vacuum. The samples were reconstituted in 500 l of assay buffer.
Antibodies
The P4 antibody (P#337 from Dr. G.D. Niswender, Colorado State University) was
diluted 1:30,000 and typically binds between 30% and 50% of [3H]P4. The 5-DHP (X-947) and
3,5-THP antibodies (#921412-5, purchased from Dr. Robert Purdy, Veterans Medical Affairs,
La Jolla, CA) was diluted 1:5000 and binds between 40-60% of [3H]3,5-THP. The 3-diol
antibody (X-144; Dr. P.N. Rao, Southwest Foundation for Biomedical Research, San Antonio,
TX) was diluted 1:20,000 and binds approximately 96% of [3H]3-diol .
Set-up and Incubation of Radioimmunoassays
The range of the standard curves were 0-8000 pg for P4, 5-DHP, and 3,5-THP, and 02000 pg for 3-diol. Standards were added to assay buffer followed by addition of the diluted
antibody and [3H] steroid. Total assay volumes were 800 l for P4, 900l for 3-diol, 950 l for
5-DHP, and 1250 l for 3,5-THP. All assays were incubated overnight at 4oC.
Termination of Binding
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Extraction of the free steroids was accomplished by the rapid addition of dextran-coated
charcoal. Following incubation with charcoal, samples were centrifuged at 3000 x g and the
supernatant was pipetted into a glass scintillation vial with 5 ml scintillation cocktail. Sample tube
concentrations were calculated using the logit-log method of Rodbard and Hutt (1974),
interpolation of the standards, and correction for recovery with Assay Zap. The logit-log method
is an empirical technique to convert the sigmoid calibration curve into a reasonably straight line,
so that a straight line approximation is acceptable. The inter- and intra-assay reliability coefficients were: for P4, 0.11 and 0.04, for 5-DHP, 0.11 and 0.04, for 3,5-THP 0.09 and 0.04,
and for 3-diol 0.09 and 0.04.
Statistical analyses
The significance of differences in estrous cyclicity were determined via chi-square
analysis. Main effects on tissue weights, neuroendocrine, and behavioral measures were evaluated
by separate one-way analyses of variance (ANOVAs) with the AED treatment condition (vehicle,
phenytoin, valproate) as the independent variable. Differences between groups were determined
via Fisher’s protected least significant differences (PLSD) post-hoc tests. The alpha level for
statistical significance was p less than 0.05. Trends were reported when p was less than 0.10.
RESULTS
Estrous Cyclicity and Uterine/Ovarian Weight
AED treatment significantly altered estrous cyclicity among female rats [χ 2(2, N = 38) =
5.67, p < 0.05]. Over the 4 week study, an average of 8 ± 2 cycles was observed. Of the thirteen
females administered phenytoin, and the thirteen females administered valproate, only two from
each group demonstrated a normal 4-5 day cycle following treatment. Of the twelve female
controls administered vehicle, nine demonstrated normal 4-5 day cycles (Figure 1). Compared to
75 % of vehicle rats which cycled properly, only 15% of phenytoin (p<.05) and 15% valproate
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rats (p<.05) cycled properly (Figure 1). Neither uterine nor ovarian weight was significantly
affected by phenytoin or valproate treatment compared to the control.

Neuroendocrine Endpoints
AED treatment significantly altered CNS steroid concentrations in some regions but not
in others. First we look at areas related to the control of sexual behaviors: the hippocampus,
midbrain, and hypothalamus. In the hippocampus, 3,5-THP levels were significantly lower in
phenytoin-administered rats in comparison to valproate and/or vehicle groups (p<.05; Figure 2
and Table 2). Phenytoin rats also exhibited a trend of increased levels of P4 in the hippocampus
compared to the vehicle group (p<.10; Table 2). There were no other differences in steroid
hormone levels of 5-DHP or 3-diol in the hippocampus.
In,the hypothalamus, phenytoin rats exhibited a trend of lower 3,5-THP levels (p<.10;
Table 2) compared to the vehicle group. There were no other differences in steroid hormone
levels of P4, 5-DHP, and 3-diol in the hypothalamus. There was also, no differences of
steroid hormone levels found in the Midbrain. Overall, in areas controlling sexual behavior there
was only altered steroid hormone differences in the hippocampus and hypothalamus, but not the
midbrain.
As a control measure, there was no difference between the phenytoin group and the
vehicle group in concentrations of P4, 5-DHP, 3,5-THP and 3-diol in the cortex, and
interbrain regions (Table 2). Phenytoin rats also exhibited no differences among serum
concentration as compared to the Vehicle group (Table 2). Although differences in steroid
hormone levels for phenytoin rats were observed in the hippocampus and hypothalamus, there
was no difference compared to the vehicle group in the midbrain, cortex, and serum.
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Valproate rats showed a significant decrease in serum P4 and a significant increase in
serum 5-DHP concentrations (p<.05; Table 2). The valproate group exhibited no difference in
comparison to the vehicle group in concentrations of P4, 5-DHP, and 3,5-THP and 3-diol
in all 5 brain regions. Overall, valproate had no effect on steroid hormone levels in the brain, but
significantly altered their concentration in the blood (Table 2).
Behavioral Endpoints
Phenytoin rats exhibited a significantly higher aggression quotient (aq) and lower
proceptivity quotient (pq) than the vehicle rats (p<.05) (Figure 3). However, phenytoin rats
showed no main effect for lordosis quotient (lq), lordosis rating (lr), mount latency or total sex
duration (Table 1).
Valproate rats showed a tendency to be more aggressive and less proceptive during sex
testing (Figure 3). Although valproate rats exhibited higher aggression and were less proceptive
during sex testing, there was no main effect for lq, lr, mount latency or total sex duration (Table
1).
DISCUSSION
Our hypothesis which stated that the anti-epileptic drug phenytoin would produce
reproductive endocrine dysfunction among female rats was supported. Eleven out of the thirteen
rats injected with phenytoin exhibited abnormal cycling compared to only three out of the eleven
rats in the control group that showed abnormal cycling. In addition, the study showed a
significant increase in aggression and a tendency to exhibit decreased proceptivity during
standard sex testing in rats treated with phenytoin. The control group of rats, treated with vehicle,
exhibited no increased aggression or decreased proceptivity or abnormal cycling in our study.
Increased aggression, and decreased proceptivity are indications of reproductive endocrine
dysfunction (Morrell, 2003).
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Our hypothesis further stated that the anti-epileptic drug phenytoin would produce
reproductive endocrine dysfunction among female rats through its effects on progesterone and its
5-reduced metabolites. Evaluation of hormone dynamics in the brain for the phenytoin rats
showed significantly lowered 3,5-THP levels in the hippocampus and hypothalamus. The
significant decrease in the 3,5-THP levels in the hippocampus correlates strongly to the
marked increase in aggressive and anti social behavior of female rats during mating. This data
correlated with our predictions and further supported our hypothesis.
These results are also consistent with previous studies. The data from this study
demonstrate that AEDs phenytoin significantly disrupt estrous cyclicity which is consistent with
the findings of Martha J. Morrell (Morell 2003; Morrell et al, 2003). To cycle properly it is
essential to have proper amounts of free steroid hormones in circulation (Frye, 2008). Enzyme
inducing AEDs reduce the levels of free steroid hormones in circulation due to the effect of
globulin-binding proteins (Morrell, 2005).
Our hypothesis which stated that the anti-epileptic drug valproate would produce
reproductive endocrine dysfunction among female rats was supported. Eleven out of the thirteen
rats injected with valproate exhibited abnormal cycling compared to only three out of the eleven
rats in the control group that showed abnormal cycling. In addition, rats treated with Valproate
showed decreased proceptivity. The control group of rats, treated with vehicle, exhibited no
decreased proceptivity and little abnormal cycling in our study. Abnormal cycling and decreased
proceptivity are indications of reproductive endocrine dysfunction (Morrell, 2005).
The data from this study demonstrate that the AED valproate significantly disrupts
estrous cyclicity which is consistent with previous studies such as the findings of Martha J.
Morrell (Morell 2003; Morrell et al, 2003). To cycle properly it is essential to have normal levels
of both estrogen and progesterone (Morrell, 2003). We predicted that valproate would produce
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reproductive endocrine dysfunction among female rats through its effects on progesterone and its
5-reduced metabolites. Our study shows that valproate significantly reduced the levels of P 4 in
serum. This disruption in the P4 concentrations caused a higher gonadal and adrenal androgen to
progesterone ratio which correlates closely with ovulatory dysfunction (Morrell and Montouris,
2004). This is consistent with the fact that valproate is documented to have strong effects on
menstrual cycles.
In addition, our study extends the current literature as it examined the dynamics of how
AEDs produce REDs by closely monitoring the role of steroid hormones in the mid brain region,
the hippocampus and hypothalamus in relation to normal sexual activity. The rats treated with
phenytoin exhibited no signs of consummatory dysfunction, but showed significant motivational
dysfunction in the form of increased aggression and antisocial behavior during mating.
Evaluation of hormone levels in the brain for these rats showed significantly lowered 3,5THP levels in the hippocampus and hypothalamus, and minimal effects on 3,5-THP levels in
the midbrain. The significant decrease in the 3,5-THP levels in the hippocampus correlates
strongly to the marked increase in aggressive and anti social behavior of female rats during
mating. The minimal effects on 3,5-THP levels in the midbrain correlates to the little, if any,
effect on the lordosis ratings and quotients of the rats in the study.

Future Direction
In the future, there are plans to repeat the same study with the addition of another AED,
lamotrogene, which is believed to have minimal, if any, effect on steroid hormones. The group
receiving lamotrogene will serve as the negative control since this specific AED is not supposed
to affect the hormone levels and thus should not produce the side effect of sexual dysfunction.
Comparing the results of the rats receiving phenytoin and valproate treatment with the negative
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control group will help us understand the effects of the treatment on sexual dysfunction in rats
more accurately. This will show whether the sexual dysfunction experienced is primarily due to
phenytoin and valproate’s effects on steroid hormones as opposed to other mechanisms.

CONCLUSION
Using a rat model made it possible to isolate the effects of phenytoin and valproate
treatments on RED independent of epilepsy. The results of the study clearly show that both
phenytoin and valproate disrupt the estrous cycle and increase reproductive endocrine
dysfunction among female rats. In addition, this study indicates that phenytoin significantly
decreases 3,5-THP levels in the hippocampus, while having no effect on the concentrations of
steroid hormones in the midbrain.
Anti-epileptic drugs have worked wonders for epileptic patients, but it is essential to reexamine their widespread use for other disorders. AEDs are often used in treating a variety of
health problems from bi-polar disorder to congenital heart defects to chronic pain. Gaining a
better and a more accurate understanding of the potential side effects of AEDs will help
physicians weigh the need for AED treatment against the side effects when considering the
drugs. Research studies such as this one will promote such understanding and may provide
helpful insights into the development of improved AED treatments.
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FIGURE LEGENDS

Figure 1 Differences in Cyclicity. Percent cycling was determined by dividing the number of
proper 4-5 day estrous cycles in assigned group divided by total number of cycles observed
(* Denotes a significant difference p <.05), (# Denotes a p< .10)
Figure 2 Differences in 3,5-THP, and 3-diol steroid hormone levels in the hippocampus.
Concentrations were calculated using the logit-log method of Rodbard and Hutt (1974),
interpolation of the standards, and correction for recovery with Assay Zap.
(* Denotes a significant difference p <.05), (# Denotes a p< .10)
Figure 3 Differences in Proceptivity and Aggressive behavior. Proceptivity quotient was
determined by number of mounts with female displaying proceptive behavior divided by number
of mounts. Aggressive quotient was determined by number of mounts followed by aggressive
behavior divided by total amount of mounts.
(* Denotes a significant difference p <.05), (# Denotes a p< .10)
Table 1: Standard Sex testing measures. Lordosis quotient was determined by number of mounts
with female displaying lordosis divided by total amount of mounts. Lordosis rating was
determined by the sum of the lordosis ratings divided by the total number of rats. Mount latency
was found by time required for male to attempt the first mount.
(* Denotes a significant difference p <.05), (# Denotes a p< .10)
Table 2: Endocrine Data. Concentrations were calculated using the logit-log method of Rodbard
and Hutt (1974), interpolation of the standards, and correction for recovery with Assay Zap.
(* Denotes a significant difference p <.05), (# Denotes a p< .10)
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Vehicle

Phenytoin

Valproate

Lordosis quotient (%)

84.2 ± 9

89.3 ± 7

85.8 ± 10

Lordosis Rating (1-4)

1.9 ± 0.2

2.0 ± 0.3

1.7 ±.25

Sex Total Duration (s)

196.3 ± 38

146.2 ± 36

170 ± 46

Mount Latency (s)

33.6 ± 15

39.5 ± 10

32.5 ± 10

Table 1
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Saline

Phenytoin

Valproate

P4

5.6 ± 2.5

3.5 ± .7

5.2 ± 2.1

5-DHP

38.9 ± 1.2

61.9 ± 18.7

68.6 ± 19.8

3,5-THP

12.7 ± 3.9

13.6 ± 5.2

8.0 ± 2.6

3-diol

7.1 ± 1.24

8.1 ± 2.5

6.5 ± 1.3

P4

6.5 ± 2.0

4.3 ± 1.3

6.8 ± 2.2

5-DHP

69.1 ± 6.2

51.0 ± 12.4

35.5 ± 15.3

3,5-THP

57.1 ± 16.7

28.0 ± 9.0 #

31.7 ± 8.7

3-diol

16.7 ± 4.9

20.9 ± 4.9

20.2 ± 4.2

P4

7.4 ± 1.8

15.9 ± 4.1 #

11.6 ± 3

5-DHP

26.8 ± 9.5

31.0 ± 7.3

14.2 ± 4.4

3,5-THP

19.8 ± 4.6

8.6 ± 2.3

22.1 ± 4.2

3-diol

4.2 ± 0.6

2.3 ± 0.5

3.7 ± 1.3

P4

14.9 ± 3

15.6 ± 2

18.4 ± 2.7

5-DHP

13.4 ± 3.7

10.8 ± 4.1

16.9 ± 4.1

3,5-THP

15.6 ± 5.1

15.2 ± 5.1

8.9 ± 3.7

3-diol

4.7 ± 1.7

3.1 ± .4

4.6 ± 1.4

P4

1.7 ± .5

1.0 ± .32

2.2 ± .76

5-DHP

39.7 ± 9.7

43.1 ± 12.6

28.2 ± 10.0

3,5-THP

13.7 ± 4.1

15.2 ± 1.5

17.1 ± 5.7

3-diol

4.9 ± 1.1

4.9 ± 1.8

3.3 ± 1.0

P4

25.0 ± 6.2

19.3 ± 4.5

12.4 ± 3.1 *

5-DHP

23.8 ± 12.4

36.2 ± 9.7

72.7 ± 14.0 *

3,5-THP

54.2 ± 11.5

29.8 ± 10.1 #

3-diol

24.6 ± 4.7

49.6 ± 12.4
18.7 ± 2.4

Midbrain

Hypothalmus

Hippocampus

Cortex

InterBrain

Serum

Table 2

21.8 ± 2.5

